Toll Free: 1-888-928-9744

Hemorrhage - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 32 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hemorrhage - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemorrhage - Pipeline Review, H2 2017, provides an overview of the Hemorrhage (Hematological Disorders) pipeline landscape.

Hemorrhage is a disease which results in excessive bleeding. Causes of hemorrhage include liver disease, bleeding disorder, high blood pressure, injury and aneurysm. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache and tingling or numbness. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemorrhage - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II and Phase 0 stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Hemorrhage (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemorrhage (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemorrhage (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemorrhage (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemorrhage (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemorrhage (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemorrhage (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemorrhage (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hemorrhage - Overview Hemorrhage - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Hemorrhage - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hemorrhage - Companies Involved in Therapeutics Development Cellphire Inc Grifols SA Haemostatix Ltd Hemorrhage - Drug Profiles (fibrinogen (human) + thrombin (human)) - Drug Profile Product Description Mechanism Of Action R&D Progress ethinylestradiol - Drug Profile Product Description Mechanism Of Action R&D Progress PeproStat - Drug Profile Product Description Mechanism Of Action R&D Progress Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Postpartum Hemorrhage - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage - Drug Profile Product Description Mechanism Of Action R&D Progress Thrombosomes - Drug Profile Product Description Mechanism Of Action R&D Progress Hemorrhage - Dormant Projects Hemorrhage - Product Development Milestones Featured News & Press Releases Mar 20, 2017: Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Hemorrhage, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Hemorrhage - Pipeline by Cellphire Inc, H2 2017 Hemorrhage - Pipeline by Grifols SA, H2 2017 Hemorrhage - Pipeline by Haemostatix Ltd, H2 2017 Hemorrhage - Dormant Projects, H2 2017


List of Figures
Number of Products under Development for Hemorrhage, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Targets, H2 2017 Number of Products by Stage and Targets, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify